Efficacy and safety of established and off‐label ADHD drug therapies for cognitive impairment or attention‐deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force
Kamilla Woznica Miskowiak, Zacharias Kalle Obel, Riccardo Guglielmo, Caterina del Mar Bonnín, Christopher R. Bowie, Vicent Balanzá‐Martínez, Katherine E. Burdick, André F. Carvalho, Annemiek Dols, Katie M. Douglas, Peter Gallagher, Lars Vedel Kessing, Beny Lafer, Kathryn E. Lewandowski, Carlos López‐Jaramillo, Anabel Martínez‐Arán, Roger S. McIntyre, Richard Porter, Scot E. Purdon, Ayal Schaffer, Paul Stokes, Tomiki Sumiyoshi, Ivan J. Torres, Tamsyn E. Van Rheenen, Lakshmi N. Yatham, Allan H. Young, Eduard Vieta, Gregor Hasler (2024). Efficacy and safety of established and off‐label ADHD drug therapies for cognitive impairment or attention‐deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force. , 26(3), DOI: https://doi.org/10.1111/bdi.13414.
